I-Mab Sponsored ADR

I-Mab is a biopharmaceutical company focused on the discovery, development, and commercialization of novel biologics to treat diseases with significant unmet medical needs, primarily cancers and autoimmune disorders. The company leverages its innovative research and development capabilities to build a robust pipeline of potential first-in-class and best-in-class drug candidates. I-Mab's strategy involves internal discovery programs and strategic partnerships to accelerate the development and commercialization of its therapeutic assets. The company aims to improve patient outcomes by bringing innovative and accessible medicines to the global market, focusing on addressing critical gaps in existing treatment options. I-Mab operates with a commitment to scientific excellence and clinical innovation, striving to transform the treatment landscape for patients worldwide.